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Background: HER2 is a known driver of breast cancer progres-
sion in 15–30% of primary breast carcinomas and an important
target for therapy. More recently, it was established that tran-
script splice variants of HER2, including delta16-HER2, herstatin,
p100 participate in malignant progression and drug resistance.
Exosomes are small vesicles of endocytic origin, which are
released by many different cell types and can be used as potential
novel biomarkers, since they contain DNA and RNA derived from
cancer cells. The aim of this study is to explore the use of
exosomes for detecting HER2 splice variants and compare levels
HER2 splice variants in cells and their exosomes.
Material and methods: Breast cancer cell lines MDA-MB-361,
MDA-MB- 231, MCF7, MCF7-Adr and BT549 were grown as mono-
layer cultures as recommended by American Type Culture Collec-
tion. The exosomes were isolated by an ultracentrifugation
protocol. Total RNA was isolated and cDNA was generated to be
used for classic PCR and SYBR Green I quantitative (q) PCR.
Results: We determined HER2 splice variants levels in MDA-
MB-361, MDA-MB-231 breast cancer cell lines and in exosomes
derived from MDA-MB-36. MDA-MB-361 cells expressed high
levels of full length HER2 mRNA, delta16-HER2 mRNA, whereas
no expression was detected in other cell lines. Exosomes derived
from MDA-MB-231 cells line were negative for Herstatin, delta16-
HER2 and p100 but positive for mRNA of full length HER2.
Conclusion: The absence of HER2 mRNA and splice variants in
MCF7, MCF7-Adr and BT549 cells lines corresponded to their
absence in exosomes. Although the other cell lines remain to be
examined, we speculate that exosomes will reflect the HER2
splice variants content present in the breast cancer cells.
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Genotoxic stress induces significant changes in expression
rates of regulatory proteins inside transformed cells. Since some
of these proteins are short-lived ones and they undergo rapid
proteasomal degradation, combined treatment with genotoxic
agent (doxorubicin) and proteasome inhibitor (bortezomib)
should launch accumulation of these proteins in cancer cells.
This accumulation is even more characteristic for the multiple
myeloma cells due to their high synthetic potential.
We investigated the pattern of regulatory proteins associated
with PSMA3 subunit of 20S proteasome core. PSMA3 is engaged
into ubiquitin-independent degradation of several proteins
known to contribute in cancer development (IjBa, p21WAF1/
CIP1). We suppose, that the proteins revealed may either be
directed to undergo ubiquitin-independent proteolysis, or possess
proteasome-regulating activity, and changes in their abundance
may not only serve as an evidence of some treatment-induced
changes, but also may be considered as biomarkers of the thera-
pies efficiency.
RPMI 8226 multiple myeloma cell line was used as a model
object. Before the actual treatment the proper apoptosis-
inducing concentrations of doxorubicin and bortezomib were
determined in order to avoid necrosis. PSMA3-interacting pro-
teins were isolated by incubation with GST-PSMA3 fusion protein
attached to glutathione sepharose beads, 2D-electrophoretically
separated and identified by MALDI TOF/TOF mass-spectrometry.
As a result we obtained heterogeneous list of proteins that can
be functionally divided into 12 subgroups: RNA turnover regula-
tors, chaperones and chaperonines, metabolic regulators, transla-
tion factors, cytoskeleton proteins, mitochondrial proteins,
transcriptional regulators, subunits of proteasomal regulatory
complexes, and several minor groups housing single members.
Due to their function and metabolism inside the cell some of
the identified proteins seem to be promising for the further inves-
tigation; among them are HuR, TUSC1 (Tumour Suppressor Can-
didate), several hnRNP representatives, numerous chaperones
(GRP78 in particular). Presence of these proteins was additionally
confirmed with immunoblotting assay, which pattern also gave
several promising guidelines for further elaboration of the data.
To exemplify, ELAVL1 (HuR) protein is known to be a protector
of mRNAs for c-myc, c-fos and some other proteins stabilising
them via binding AU-rich sequences in 30-UTR. As far as protea-
somes are also capable to recognise these motifs and moreover
possess RNAse activity, these two processes might compete
within the cell. According to immunoblotting patterns after drug
treatment of the cells HuR is significantly accumulated; this sup-
ports our assumption of it being degraded via proteasome-
independent proteolysis. Relying on the obtained data this
hypothesis and several others are being tested.
Present work was supported by RFBR (Projects 12-04-01397 and 15-
04-04541).
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Background: Breast cancer is the most common cause of death
from cancer among women aged 40–69 years. According to WHO,
about 1 million new cases of breast cancer are diagnosed annually
worldwide, and nearly 500,000 die from it. In Russia, more than
55,000 women are diagnosed with breast cancer annually, and
more than 22,000 die from it. Diagnosis and treatment of breast
cancer is the primary and important social and medical
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problem.The increased expression of: (a) ER and PgR (70–75% of all
cases of breast cancer) is an indication for hormone therapy,
which is one of the simplest and most effective methods of
systemic treatment of breast cancer; (b) receptor HER2/neu is a
marker of highly aggressive form of breast cancer and indication
for the use of targeted therapy Gertseptin; (c) proliferative factor
Ki-67 reflects the ability of a tumor to metastasize.
Today, the ‘‘gold standard” of gene expression diagnostic of ER,
PgR, HER2/neu and Ki-67 in breast cancer is immunohistochem-
istry (IHC) using foreign test systems (Ventana, Dako Inc, USA) .
However, IHC diagnostics has some significant drawbacks. It
leads up to 15–17% of cases of incorrect choice of drug therapy,
which based on incorrect results of IHC studies. As a result, the
significant group of patients do not receive effective treatment.
Aim of the study Aim: the development a prototype of diagnostic
test system for detection the receptor status of breast cancer,
based on RT-PCR.
Materials and methods: Breast cancersamples consisted of 45
fresh-frozen tissue (FFT) samples of breast cancer (sites of malig-
nant transformation and normal tissue from the same patients)
and 59 FFPET sampleswere collected. All the samples had the
IHC characteristic of receptor status of ER, PgR, HER2/neu and
proliferation factor Ki-67 (Dako Inc., USA). Samples were submit-
ted by SBIH NR ‘‘Novosibirsk Regional Oncology Center” (Novosi-
birsk, Russia). The experimental part of the study was divided
into several stages: separation of mRNA from cells, obtaining
cDNA (reverse transcription reaction), PCR in real-time and vali-
dation of the test system. Isolation of total RNA from FFT samples
was performed using a set of ‘‘SV Total RNA Isolation system”
according to the manufacturer’s instructions (Promega, USA). Iso-
lation of total RNA from FFPET samples was performed using a set
‘‘ReliaPrep FFPE Total RNA Miniprep System” (Promega, USA)
according to the manufacturer’s instructions. The concentration
of total RNA was determined using a NanoDrop 1000 microspec-
trophotometer (Thermo Bioscience, USA) (RNA concentration
were 15–660 ng/ml).
Results: For the reverse transcription reaction (RT) and PCR,
the main parameters were selected. For RT: RNA incubation time
and temperature of the reaction, enzyme concentration in the
reaction mix. For PCR: the amount of DNA template, the number
of primers, the concentration of magny ions, the concentration of
the polymerase. Validation of the developed test system was car-
ried out by comparing the results obtained by RT-PCR with the
results of the IHC analysis of the same samples. Statistical pro-
cessing of the research results was performed using the MedCalc
program v.14.12.0 (Microsoft Corp.).
Conclusion: We have considered modern advanced methods of
diagnostic of breast cancer receptor status. It was concluded that
the use of RT-PCR in real time technology is the best alternative
technology of the IHC, which currently is the standard definition
of the expression of ER, PgR, HER2/neu and Ki-67. Prototype of test
system for the detection of ER, PgR, HER2/neu and Ki67 prolifera-
tive factor in breast cancer samples was designed and optimized
by RT-PCR.
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Glucocorticoids (GCs) are widely used in treatment of many
cancer types due to its ability to induce apoptosis in malignant
cells in blood cancer therapy, and to prevent nausea, emesis
and chemotherapy-associated hepatotoxicity in case of solid
tumors. However, severe dose-limiting side effects occur, includ-
ing osteoporosis, diabetes and other metabolic complications.
Moreover, in therapy of solid tumors GCs strongly affect microen-
vironment which could be associated with poor prognosis, risk of
metastasis and high frequency of relapses.
Biological response to GCs is mediated by glucocorticoid
receptor (GR), a well-characterized transcription factor. GR
controls gene expression via (1) transactivation, which requires
binding of GR homodimers to glucocorticoid-responsive elements
(GRE) in gene promoters and enhancers, and (2) dimerization-
independent transrepression mediated via negative interaction
between GR and other transcription factors including major effec-
tors of inflammation and proliferation. Transrepression plays an
important role in anti-inflammatory and anti-cancer effects of
GR, including normalizing influence on microenvironment, while
side effects are associated with GR transactivation. In particular,
GCs induce insulin resistance in adipocytes, a major component
of the mammary microenvironment, which secrete pro-
inflammatory cytokines and growth factors, implicated in tumor
progression. Selective GR agonists (SEGRA) that preferentially
activate GR transrepression could be a better option for treatment
of cancer.
Dozens of candidate SEGRAs were identified, synthesized and
tested by industry and academia, with some having reached clin-
ical trials. One of the novel GR modulators is 2-(4-acetoxyphenyl)-
2-chloro-N-methylethylammonium-chloride, or CpdA, synthetic
analogue of aziridine precursor isolated from Namibian shrub
Salsola tuberculatiformis Botschantzev. It was shown that CpdA
acts as ‘‘dissociated” GR ligand: it competes with GCs for GR
binding and efficiently induces GR transrepression but not
transactivation. We and other authors reported recently that
CpdA inhibits survival of prostate cancer cells as well as blood
cancer cells in GR-dependent fashion. Furthermore, primary leu-
kemia cells from T-ALL patients appeared to be equally sensitive
to GCs and CpdA.
Our further studies were concentrated on three directions:
(1) GC/SEGRA-based chemotherapy. We screened biological
effect of CpdA in combination with traditional agents
(doxorubicin, vincristine) and newer therapeutics (Bortezomib,
Carfilzomib, MLN-4924, Rapamycin). Pretreatment of lymphoma
cells with proteasome inhibitor Bortezomib resulted in GR
accumulation and enhanced ligand properties of CpdA. We also
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